mitotic spindle organizing protein 2AGenealiases: FAM128A · MOZART2A
Q-omics provides the consensus-scored MZT2A profile across patient tissues and cancer cell-line models. MZT2A expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, MZT2A is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, MZT2A RNA expression shows 17,745 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, KIRC, and THYM as cancer lineages where MZT2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MZT2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MZT2A survival associations across molecular data types. MZT2A RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MZT2A RNA expression–survival associations across cancer types. High MZT2A expression shows unfavorable associations in KIRP, LIHC, LUAD and ACC, but favorable associations in BRCA and OV. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for MZT2A RNA expression.
This table summarizes MZT2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MZT2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MZT2A shows higher tumor expression in KIRC, KIRP, COAD, BLCA, LUAD and LUSC. The KIRC box plot shows higher MZT2A RNA expression in tumor versus normal tissue (log2 FC = +1.887, t-test p < 0.001).
This table shows molecular features associated with MZT2A in patient tissues and cancer cell lines. In patient samples, MZT2A shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, MZT2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SOFT_TISSUE.
